JP2020507606A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507606A5 JP2020507606A5 JP2019543998A JP2019543998A JP2020507606A5 JP 2020507606 A5 JP2020507606 A5 JP 2020507606A5 JP 2019543998 A JP2019543998 A JP 2019543998A JP 2019543998 A JP2019543998 A JP 2019543998A JP 2020507606 A5 JP2020507606 A5 JP 2020507606A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- ethyl
- methyl
- alkyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 91
- 125000000217 alkyl group Chemical group 0.000 claims description 90
- 150000003839 salts Chemical class 0.000 claims description 77
- -1 N, N-dimethylaminoethyl Chemical group 0.000 claims description 59
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 102000001708 Protein Isoforms Human genes 0.000 claims description 14
- 108010029485 Protein Isoforms Proteins 0.000 claims description 14
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 230000009286 beneficial effect Effects 0.000 claims description 7
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 108090000312 Calcium Channels Proteins 0.000 claims description 6
- 102000003922 Calcium Channels Human genes 0.000 claims description 6
- 102000003691 T-Type Calcium Channels Human genes 0.000 claims description 6
- 108090000030 T-Type Calcium Channels Proteins 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims description 3
- 244000250129 Trigonella foenum graecum Species 0.000 claims description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- IWJOAMCMDKUPSS-NMMIHGMASA-N 3-[(1S,2S)-2-[2-[3-[4,6-bis(trifluoromethyl)-1H-benzimidazol-2-yl]propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl]morpholine-4-carboxylic acid Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=C(C=C(C=C4N3)C(F)(F)F)C(F)(F)F)C5COCCN5C(=O)O)C=C(C=C2)F IWJOAMCMDKUPSS-NMMIHGMASA-N 0.000 claims description 2
- IWJOAMCMDKUPSS-UHFFFAOYSA-N 3-[2-[2-[3-[4,6-bis(trifluoromethyl)-1H-benzimidazol-2-yl]propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl]morpholine-4-carboxylic acid Chemical compound CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=C(C=C(C=C4N3)C(F)(F)F)C(F)(F)F)C5COCCN5C(=O)O)C=C(C=C2)F IWJOAMCMDKUPSS-UHFFFAOYSA-N 0.000 claims description 2
- HLKUAFQXZIWWAX-UHFFFAOYSA-N CC(C)C(C(CCN(C)CCC(C)(C)C1=NC(C=CC=C2)=C2N1)(CCC1=C2)C(COCC3)N3C(O)=O)C1=CC=C2F Chemical compound CC(C)C(C(CCN(C)CCC(C)(C)C1=NC(C=CC=C2)=C2N1)(CCC1=C2)C(COCC3)N3C(O)=O)C1=CC=C2F HLKUAFQXZIWWAX-UHFFFAOYSA-N 0.000 claims description 2
- VFGMKSLSMTYVIH-UHFFFAOYSA-N CC(C)C(C(CCN(C)CCC(C)(C)C1=NC(C=CC=C2)=C2N1)(CNC(O)=O)CCC1=C2)C1=CC=C2F Chemical compound CC(C)C(C(CCN(C)CCC(C)(C)C1=NC(C=CC=C2)=C2N1)(CNC(O)=O)CCC1=C2)C1=CC=C2F VFGMKSLSMTYVIH-UHFFFAOYSA-N 0.000 claims description 2
- YVSVPYDBLWZNOA-UHFFFAOYSA-N CC(C)C(C(CCN(C)CCC1(CC1)C1=NC(C=CC=C2)=C2N1)(CCC1=C2)C(COCC3)N3C(O)=O)C1=CC=C2F Chemical compound CC(C)C(C(CCN(C)CCC1(CC1)C1=NC(C=CC=C2)=C2N1)(CCC1=C2)C(COCC3)N3C(O)=O)C1=CC=C2F YVSVPYDBLWZNOA-UHFFFAOYSA-N 0.000 claims description 2
- HHNVXQFSIYTYLZ-UHFFFAOYSA-N CC(C)C(C(CCN(C)CCCC1=NC(C(C)=CC=C2C)=C2N1)(CCC1=C2)C(COCC3)N3C(O)=O)C1=CC=C2F Chemical compound CC(C)C(C(CCN(C)CCCC1=NC(C(C)=CC=C2C)=C2N1)(CCC1=C2)C(COCC3)N3C(O)=O)C1=CC=C2F HHNVXQFSIYTYLZ-UHFFFAOYSA-N 0.000 claims description 2
- GFAVBVNVVBMGRL-UHFFFAOYSA-N CC(C)C(C(CCN(C)CCCC1=NC(C(OC)=CC=C2OC)=C2N1)(CNC(O)=O)CCC1=C2)C1=CC=C2F Chemical compound CC(C)C(C(CCN(C)CCCC1=NC(C(OC)=CC=C2OC)=C2N1)(CNC(O)=O)CCC1=C2)C1=CC=C2F GFAVBVNVVBMGRL-UHFFFAOYSA-N 0.000 claims description 2
- ARFGYDRJRJNMQI-UHFFFAOYSA-N CC(C)C1C2=C(C=C(C=C2)F)OCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)CNC(=O)O Chemical compound CC(C)C1C2=C(C=C(C=C2)F)OCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)CNC(=O)O ARFGYDRJRJNMQI-UHFFFAOYSA-N 0.000 claims description 2
- DXZSWYQYGILTFX-UHFFFAOYSA-N CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=C(C=CC(=C4N3)OC)Cl)CN(C)C(=O)O)C=C(C=C2)F Chemical compound CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=C(C=CC(=C4N3)OC)Cl)CN(C)C(=O)O)C=C(C=C2)F DXZSWYQYGILTFX-UHFFFAOYSA-N 0.000 claims description 2
- HLKUAFQXZIWWAX-LMALLOCISA-N CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCC(C)(C)C3=NC4=CC=CC=C4N3)C5COCCN5C(=O)O)C=C(C=C2)F Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCC(C)(C)C3=NC4=CC=CC=C4N3)C5COCCN5C(=O)O)C=C(C=C2)F HLKUAFQXZIWWAX-LMALLOCISA-N 0.000 claims description 2
- VFGMKSLSMTYVIH-FREGXXQWSA-N CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCC(C)(C)C3=NC4=CC=CC=C4N3)CNC(=O)O)C=C(C=C2)F Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCC(C)(C)C3=NC4=CC=CC=C4N3)CNC(=O)O)C=C(C=C2)F VFGMKSLSMTYVIH-FREGXXQWSA-N 0.000 claims description 2
- YVSVPYDBLWZNOA-LMALLOCISA-N CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCC3(CC3)C4=NC5=CC=CC=C5N4)C6COCCN6C(=O)O)C=C(C=C2)F Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCC3(CC3)C4=NC5=CC=CC=C5N4)C6COCCN6C(=O)O)C=C(C=C2)F YVSVPYDBLWZNOA-LMALLOCISA-N 0.000 claims description 2
- DXZSWYQYGILTFX-FREGXXQWSA-N CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=C(C=CC(=C4N3)OC)Cl)CN(C)C(=O)O)C=C(C=C2)F Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=C(C=CC(=C4N3)OC)Cl)CN(C)C(=O)O)C=C(C=C2)F DXZSWYQYGILTFX-FREGXXQWSA-N 0.000 claims description 2
- GFAVBVNVVBMGRL-FREGXXQWSA-N CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=C(C=CC(=C4N3)OC)OC)CNC(=O)O)C=C(C=C2)F Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=C(C=CC(=C4N3)OC)OC)CNC(=O)O)C=C(C=C2)F GFAVBVNVVBMGRL-FREGXXQWSA-N 0.000 claims description 2
- OPNJAZPBIWUKOY-XTEPFMGCSA-N CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)CNC(=O)O)C=C(C=C2)F Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)CNC(=O)O)C=C(C=C2)F OPNJAZPBIWUKOY-XTEPFMGCSA-N 0.000 claims description 2
- HFCJAYMEPWMHCS-UHFFFAOYSA-N CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CCC3(CCC4=C(C3C(C)C)C=CC(=C4)F)CN(C)C(=O)O Chemical compound CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CCC3(CCC4=C(C3C(C)C)C=CC(=C4)F)CN(C)C(=O)O HFCJAYMEPWMHCS-UHFFFAOYSA-N 0.000 claims description 2
- HHNVXQFSIYTYLZ-CMNOXULISA-N CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@@]3(CCC4=C([C@H]3C(C)C)C=CC(=C4)F)C5COCCN5C(=O)O Chemical compound CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@@]3(CCC4=C([C@H]3C(C)C)C=CC(=C4)F)C5COCCN5C(=O)O HHNVXQFSIYTYLZ-CMNOXULISA-N 0.000 claims description 2
- HHNVXQFSIYTYLZ-ZOAJNJICSA-N CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@]3(CCC4=C([C@@H]3C(C)C)C=CC(=C4)F)C5COCCN5C(=O)O Chemical compound CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@]3(CCC4=C([C@@H]3C(C)C)C=CC(=C4)F)C5COCCN5C(=O)O HHNVXQFSIYTYLZ-ZOAJNJICSA-N 0.000 claims description 2
- HFCJAYMEPWMHCS-JTSJOTPCSA-N CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@]3(CCC4=C([C@@H]3C(C)C)C=CC(=C4)F)CN(C)C(=O)O Chemical compound CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@]3(CCC4=C([C@@H]3C(C)C)C=CC(=C4)F)CN(C)C(=O)O HFCJAYMEPWMHCS-JTSJOTPCSA-N 0.000 claims description 2
- RFZTVUJIENHCBI-FREGXXQWSA-N CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@]3(CCC4=C([C@@H]3C(C)C)C=CC(=C4)F)CNC(=O)O Chemical compound CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@]3(CCC4=C([C@@H]3C(C)C)C=CC(=C4)F)CNC(=O)O RFZTVUJIENHCBI-FREGXXQWSA-N 0.000 claims description 2
- PJDNSIZKNZNKCJ-UVOPUAODSA-N CCN(CCCC(=O)NC1=C(C=CC(=C1N)C)C)CC[C@]2(CCC3=C([C@@H]2C(C)C)C=CC(=C3)F)C4COCCN4C(=O)O Chemical compound CCN(CCCC(=O)NC1=C(C=CC(=C1N)C)C)CC[C@]2(CCC3=C([C@@H]2C(C)C)C=CC(=C3)F)C4COCCN4C(=O)O PJDNSIZKNZNKCJ-UVOPUAODSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 0 CC(CC=C1C)c2c1nc(*)[n]2C Chemical compound CC(CC=C1C)c2c1nc(*)[n]2C 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 2
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- GSWJJXXRQOXFCP-UHFFFAOYSA-N CC(C)c1nc(C=CCC2)c2[n]1C Chemical compound CC(C)c1nc(C=CCC2)c2[n]1C GSWJJXXRQOXFCP-UHFFFAOYSA-N 0.000 description 1
- GWZLMUNEDVTESN-UHFFFAOYSA-N Cc1nc(c(OC)ccc2OC)c2[nH]1 Chemical compound Cc1nc(c(OC)ccc2OC)c2[nH]1 GWZLMUNEDVTESN-UHFFFAOYSA-N 0.000 description 1
- NKHMPCKGOLWJGH-MSLMYCKWSA-N Cc1ncc(/C(/Cl)=C\C=C\OC)[nH]1 Chemical compound Cc1ncc(/C(/Cl)=C\C=C\OC)[nH]1 NKHMPCKGOLWJGH-MSLMYCKWSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459355P | 2017-02-15 | 2017-02-15 | |
| US62/459,355 | 2017-02-15 | ||
| PCT/US2018/018356 WO2018152317A1 (en) | 2017-02-15 | 2018-02-15 | Calcium channel inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020507606A JP2020507606A (ja) | 2020-03-12 |
| JP2020507606A5 true JP2020507606A5 (enExample) | 2021-03-25 |
| JP7134178B2 JP7134178B2 (ja) | 2022-09-09 |
Family
ID=63170001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543998A Active JP7134178B2 (ja) | 2017-02-15 | 2018-02-15 | カルシウムチャネル阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11130750B2 (enExample) |
| EP (1) | EP3585376A4 (enExample) |
| JP (1) | JP7134178B2 (enExample) |
| KR (1) | KR102642063B1 (enExample) |
| CN (1) | CN110545806A (enExample) |
| AU (1) | AU2018221722B2 (enExample) |
| CA (1) | CA3053781A1 (enExample) |
| WO (1) | WO2018152317A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| BR112021013766A2 (pt) | 2019-03-01 | 2021-09-21 | Flamel Ireland Limited | Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ213651A (en) * | 1984-10-11 | 1989-07-27 | Hoffmann La Roche | Tetrahydronapthalene derivatives and medicaments |
| CA1319144C (en) * | 1986-11-14 | 1993-06-15 | Quirico Branca | Tetrahydronaphthalene derivatives |
| WO1993004047A1 (en) | 1991-08-16 | 1993-03-04 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| DK0882061T3 (da) | 1996-02-14 | 2004-09-27 | Isis Pharmaceuticals Inc | Sukkermodificerede gapped oligonukleotider |
| WO2001062740A1 (en) | 2000-02-25 | 2001-08-30 | South Alabama Medical Science Foundation | Mibefradil analogues and their use |
| WO2003062421A1 (en) | 2002-01-17 | 2003-07-31 | The University Of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| AU2003277418A1 (en) | 2002-10-17 | 2004-05-04 | Merck And Co., Inc. | Enhancement of sleep with t-type calcium channel antagonists |
| US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| KR100610731B1 (ko) | 2004-02-24 | 2006-08-09 | 한국과학기술연구원 | Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법 |
| US7504431B2 (en) | 2004-04-16 | 2009-03-17 | Bristol-Myers Squibb Company | Sulfonyl amide inhibitors of calcium channel function |
| CA2576191C (en) | 2004-08-20 | 2013-03-19 | University Of Virginia Patent Foundation | T type calcium channel inhibitors |
| CA2576186A1 (en) | 2004-08-20 | 2006-03-02 | University Of Virginia Patent Foundation | T type calcium channel blockers and the treatment of diseases |
| WO2006098969A2 (en) | 2005-03-09 | 2006-09-21 | Merck & Co., Inc. | Quinazolinone t-type calcium channel antagonists |
| US20100222387A1 (en) | 2005-06-23 | 2010-09-02 | Barrow James C | 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists |
| JP2009500340A (ja) | 2005-06-29 | 2009-01-08 | メルク エンド カムパニー インコーポレーテッド | ４−フルオロ−ピペリジンｔ型カルシウムチャネルアンタゴニスト |
| WO2007007852A1 (ja) | 2005-07-14 | 2007-01-18 | Teijin Chemicals Ltd. | 発泡樹脂シートおよび液晶表示装置 |
| KR100654328B1 (ko) | 2005-08-26 | 2006-12-08 | 한국과학기술연구원 | 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법 |
| AU2006327173A1 (en) | 2005-12-22 | 2007-06-28 | Icagen, Inc. | Calcium channel antagonists |
| US7875636B2 (en) | 2006-04-12 | 2011-01-25 | Merck Sharp & Dohme Corp. | Pyridyl amide T-type calcium channel antagonists |
| KR100743255B1 (ko) | 2006-05-04 | 2007-07-27 | 한국과학기술연구원 | Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체 |
| KR100749843B1 (ko) | 2006-07-13 | 2007-08-21 | 한국과학기술연구원 | Ｔ-타입 칼슘 채널에 억제 활성을 지닌 신규2,4-디옥소-퀴나졸린 유도체 및 이의 제조방법 |
| KR100969686B1 (ko) | 2006-08-07 | 2010-07-14 | 한국과학기술연구원 | 신규한 티아졸계 화합물 및 이를 함유하는 ｔ-형 칼슘 채널저해제 |
| JP2010503675A (ja) | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体 |
| MX2009002918A (es) | 2006-09-15 | 2009-03-31 | Schering Corp | Derivados azetidinona y sus metodos de uso. |
| MX2009002921A (es) | 2006-09-15 | 2009-04-01 | Schering Corp | Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico. |
| US20080070888A1 (en) | 2006-09-15 | 2008-03-20 | Mckittrick Brian A | Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism |
| AR062841A1 (es) | 2006-09-15 | 2008-12-10 | Schering Corp | Tratamiento del dolor, diabetes, y trastornos del metabolismo de los lipidos |
| WO2008050200A1 (en) | 2006-10-24 | 2008-05-02 | Pfizer Products Inc. | Oxadiazole compounds as calcium channel antagonists |
| EP2073799A4 (en) | 2007-03-12 | 2009-08-19 | Vm Discovery Inc | NOVEL ACTIVE SUBSTANCES FROM CALCIUMIONAL CHANNEL MODULATORS |
| US20080227823A1 (en) | 2007-03-12 | 2008-09-18 | Hassan Pajouhesh | Amide derivatives as calcium channel blockers |
| WO2008117148A1 (en) | 2007-03-23 | 2008-10-02 | Pfizer Products Inc. | Substituted oxadiazole analogs as calcium channel antagonists |
| WO2008138126A1 (en) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
| KR100863239B1 (ko) | 2007-05-23 | 2008-10-15 | 한국과학기술연구원 | 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제 |
| AU2008275674A1 (en) | 2007-07-10 | 2009-01-15 | Merck & Co., Inc. | Quinazolinone T-type calcium channel antagonists |
| KR101079459B1 (ko) | 2007-09-14 | 2011-11-03 | 이화여자대학교 산학협력단 | 신규한 화합물, 이의 제조방법 및 이를 포함하는 통증억제용 조성물 |
| US20100216816A1 (en) | 2007-10-24 | 2010-08-26 | Barrow James C | Pyrazinyl amide-t type calcium channel antagonists |
| KR20100072266A (ko) | 2007-10-24 | 2010-06-30 | 머크 샤프 앤드 돔 코포레이션 | 헤테로사이클 페닐 아미드 ｔ-형 칼슘 채널 길항제 |
| CA2702126A1 (en) | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Heterocycle amide t-type calcium channel antagonists |
| WO2009056934A1 (en) | 2007-10-31 | 2009-05-07 | Pfizer Products Inc. | 1,4-dihydronaphthyridine derivatives |
| KR100917037B1 (ko) | 2007-11-01 | 2009-09-10 | 한국과학기술연구원 | 피라졸릴카르복스아미도알킬피페라진 유도체 및 이의제조방법 |
| WO2009132454A1 (en) | 2008-04-28 | 2009-11-05 | Neuromed Pharmaceuticals Ltd. | Di-t-butylphenyl piperazines as calcium channel blockers |
| US8377968B2 (en) | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| US20090298834A1 (en) | 2008-06-02 | 2009-12-03 | Hassan Pajouhesh | 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers |
| KR101014887B1 (ko) | 2008-06-26 | 2011-02-15 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 이미다졸릴알킬카르보닐유도체 및 그의 제조방법 |
| KR20100005476A (ko) | 2008-07-07 | 2010-01-15 | 한국과학기술연구원 | Ｔ-형 칼슘 채널에 활성을 지닌 신규 아이소인돌리논유도체 및 이의 제조방법 |
| KR101052620B1 (ko) | 2008-08-28 | 2011-07-29 | 한국과학기술연구원 | 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 |
| KR101052065B1 (ko) | 2008-10-15 | 2011-07-27 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법 |
| TW201028421A (en) | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
| KR20120030112A (ko) | 2009-06-05 | 2012-03-27 | 타우 쎄라퓨틱스 엘엘씨 | 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법 |
| CN102781316B (zh) | 2010-03-01 | 2016-07-06 | 陶制药有限责任公司 | 癌症诊断和成像 |
| US8575361B2 (en) | 2010-03-02 | 2013-11-05 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
| WO2012094615A2 (en) | 2011-01-07 | 2012-07-12 | Zenyaku Kogyo Kabushikikaisha | Use of cav3.1 selective t-type calcium channel antagonists |
| EP2846792B1 (en) | 2012-05-08 | 2018-08-15 | Zafgen, Inc. | Treating hypothalamic obesity with metap2 inhibitors |
| US20150355163A1 (en) | 2013-01-10 | 2015-12-10 | Tau Therapeutics Llc | T-type calcium channel inhibitors for treatment of cancer |
| KR101679262B1 (ko) * | 2015-06-08 | 2016-11-24 | 한국과학기술연구원 | 4-이소프로필크로만-3-올 화합물 |
| EP3364993B1 (en) | 2015-10-22 | 2022-11-09 | Cavion, Inc. | Methods for treating angelman syndrome |
| CA3061712A1 (en) | 2017-04-26 | 2018-11-01 | Cavion, Inc. | Methods for treating dravet syndrome |
| EP3615521A4 (en) | 2017-04-26 | 2021-02-17 | Cavion, Inc. | METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS |
-
2018
- 2018-02-15 CN CN201880024040.6A patent/CN110545806A/zh active Pending
- 2018-02-15 WO PCT/US2018/018356 patent/WO2018152317A1/en not_active Ceased
- 2018-02-15 CA CA3053781A patent/CA3053781A1/en active Pending
- 2018-02-15 EP EP18755079.3A patent/EP3585376A4/en active Pending
- 2018-02-15 US US16/486,399 patent/US11130750B2/en active Active
- 2018-02-15 JP JP2019543998A patent/JP7134178B2/ja active Active
- 2018-02-15 KR KR1020197027037A patent/KR102642063B1/ko active Active
- 2018-02-15 AU AU2018221722A patent/AU2018221722B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016053042A5 (enExample) | ||
| JP2012508252A5 (enExample) | ||
| JP2021515033A5 (enExample) | ||
| JP2014503567A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| JP2014051526A5 (enExample) | ||
| JP2016513737A5 (enExample) | ||
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2009504764A5 (enExample) | ||
| JP2017528524A5 (enExample) | ||
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| JP2019507114A5 (enExample) | ||
| JP2014520108A5 (enExample) | ||
| JP2020527173A5 (enExample) | ||
| CN111601797A (zh) | 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 | |
| MA30315B1 (fr) | Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| JP2012519703A5 (enExample) | ||
| JP2023512206A5 (enExample) | ||
| JP2023512227A5 (enExample) | ||
| JP2023525359A5 (enExample) |